Pay in 4 interest-free payments of $6.88 Learn more
Ships within 48 hours · Estimated delivery Oct 2 - Oct 7
Typical protocol: Dose: 12 mg subcutaneously daily Duration: 812 weeks for visible skin changes Can also be used topically (0.51% in carrier solution) KPV: The Targeted Anti-Inflammatory KPV is a tripeptide (lysine-proline-valine) derived from alpha-MSH (alpha-melanocyte-stimulating hormone)
Achieved IgG reduction is similar to that achieved by nipocalimab in human FcRn transgenic mice [360], and a concomitant therapeutic effect has been observed in animal models of arthritis, ITP and glomerulonephritis [414,415,416] and in clinical trials assessing safety (NCT01802697), increasing transplant success by negating pre-existing immunity (NCT02224820, NCT02426684, and NCT02475551), and in thrombotic thrombocytopenic purpura (NCT02854059)
Small, simple structures resist thermal degradation better
For subcutaneous administration, 250-500 mcg per day represents the standard range, with some protocols using 300 mcg as a target dose
US$ 21.80
US$ 28.01
US$ 22.90
US$ 29.90
US$ 27.63
US$ 22.04
